



BioLight Life Sciences Ltd.
(the “Company”)

October 31 2023

Re: FDA registration for Peripherex’ Product

The Company announces that Peripherex Inc. (“Peripherex”), one of its portfolio companies, which develops a software-based product for monitoring and diagnosing peripheral vision impairment using a personal computer and its built-in camera through eye movement tracking (the “Product”), has informed it that on October 30, 2023, it has successfully registered the Product with the FDA¹ and can now begin marketing and selling its peripheral vision impairment monitoring Product for home use and relevant clinics.

The FDA registration was based, among other things, on tests that showed a good match between the test results using the Product and the test results in a device that is currently common in the world and is found in certain clinics and institutes².

As informed to BioLight, the main advantages inherent in the Product are: the ability to perform frequent home monitoring of the change in peripheral vision according to the patient's wishes and the instructions of the attending doctor; receiving ongoing information and alerts from the attending doctor regarding changes in peripheral vision; the examination is simple to perform and takes only about 3 minutes per eye and can be done at home or in a private clinic and does not require a visit to institutes nor use of special equipment and technicians as is done today.

¹ The Product is classified as Class I device

² Humphrey Visual Field Analyzer by Zeiss

Forward Looking Statement *The information and details contained in this report regarding the receipt of FDA approval as well as predictions and/or plans following receipt of the FDA approval are "Forward-looking information" as defined in the Israeli Securities Law, 1968-5778 which involves high uncertainty, and are based, among other things, on third parties and on many variables over which the Company and/or Peripherex do not necessarily have control, and therefore it is possible that the aforementioned information and estimates, in practice will not be realized and/or will not be fully realized and/or will be realized in a materially different way than was initially estimated or observed, including as a result of any of the risk factors as detailed in Section 4.27 in Chapter A of the Company's annual report, which may have a significant effect, together and separately, on the Company's estimates as mentioned above.*

About Peripherex

Peripherex develops a software-based product for monitoring and diagnosing peripheral vision impairment using a personal computer and its built-in camera through eye movement tracking. The test is intended to check for suspicion or development of glaucoma and other eye diseases that affect peripheral vision. Peripherex was founded by and based on an invention by Professor Jeffrey Goldberg, who serves as the Chair of Ophthalmology at the Byers Institute at Stanford University in the United States and in collaboration with the Israeli company UMOOVE.

About BioLight

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects in the field of eye diseases and ocular treatments. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine designed to improve the efficacy and safety of treatments of eye diseases exemplifying the enormous potential of Israeli innovation in these fields.

Free translation: non-binding.

This is a translated version of the Company's immediate report in Hebrew as filed with the Israeli Securities' Authorities – created for convenience purposes only. In case of contradiction, the Hebrew version will take precedence.